Acceleron Pharma Inc (XLRN): John L Knopf , CEO and President of Acceleron Pharma Inc sold 100,000 shares on May 18, 2016. The Insider selling transaction was reported by the company on May 20, 2016 to the Securities and Exchange Commission. The shares were sold at $33.08 per share for a total value of $3,307,352.25 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 8, 2016, Steven D Ertel (EVP & Chief Operating Officer) sold 32,270 shares at $32.00 per share price.On Apr 8, 2016, Matthew L Sherman (EVP & Chief Medical Officer) sold 26,000 shares at $32.00 per share price.Also, On Jan 11, 2016, Corp /de/ Celgene (10% owner) purchased 800,000 shares at $40.00 per share price.On Oct 9, 2015, John L Knopf (CEO and President) sold 19,000 shares at $24.30 per share price.
Acceleron Pharma Inc: On Thursday, May 19, 2016 heightened volatility was witnessed in Acceleron Pharma Inc which led to swings in the share price. The shares opened for trading at $32.64 and hit $33.3 on the upside , eventually ending the session at $32.95, with a gain of 0.18% or 0.06 points. The heightened volatility saw the trading volume jump to 3,94,057 shares. The 52-week high of the share price is $50.86 and the company has a market cap of $1,226,432 M . The 52-week low of the share price is at $20.
Company has been under the radar of several Street Analysts.Acceleron Pharma Inc is Initiated by Barclays to Overweight and the brokerage firm has set the Price Target at $40. The Rating was issued on Apr 27, 2016.
Acceleron Pharma Inc. is a biopharmaceutical company focused on the discovery development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company’s research focuses on key natural regulators of cellular growth and repair particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. By combining its discovery and development know-how including its knowledge of the TGF-b superfamily and its internal protein engineering and manufacturing capabilities the Company has built a discovery and development platform that has generated therapeutic candidates with new mechanisms of action. The Company has four internally discovered therapeutic candidates that are in clinical trials.